Podcast appearances and mentions of jeff ratliff

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Per Borghammer explore the subcategories of Lewy body disease, focusing on the body-first subtype Show reference: https://www.nature.com/articles/s41593-025-01910-9 

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Per Borghammer examine the dichotomy that existed before his team began this project. Show reference: https://www.nature.com/articles/s41593-025-01910-9 

Dr. Jeff Ratliff talks with Dr. Per Borghammer about the classification of Lewy body disease into brain-first and body-first subtypes, with a focus on the newly identified parasympathetic and sympathetic subtypes within the body-first category.  Read the related article in Nature.  Disclosures can be found at Neurology.org. 

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Harry Sutherland discuss the diverse strategies that residency programs implement to ensure residents can continue their education in a protected and supportive environment.  Show reference: https://www.neurology.org/doi/10.1212/NE9.0000000000200205 

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Harry Sutherland discuss how neurology residency programs are incorporating didactic teaching methods to enhance learning outside the clinical environment. Show reference: https://www.neurology.org/doi/10.1212/NE9.0000000000200205 

Dr. Jeff Ratliff talks with Dr. Harry W. Sutherland about diversity in teaching methods, the balance between clinical responsibilities and educational opportunities, and innovative models like the academic half day. Read the related article in Neurology® Education. Disclosures can be found at Neurology.org. 

Neurology® Open Access has officially launched!  In part two of this two-part series, Dr. Jeff Ratliff and Dr. Amy C. Kunchok discuss the advantages of an open-access publication model. Read the related editorial in Neurology® Open Access.

Neurology® Open Access has officially launched!  In part one of this two-part series, Dr. Jeff Ratliff and Dr. Amy C. Kunchok discuss the scope and focus of Neurology® Open Access (NOA). Read the related editorial in Neurology® Open Access.  

Neurology® Open Access has officially launched.  In this episode, Dr. Jeff Ratliff and NOA Editor, Dr. Amy C. Kunchok share insights about Neurology® Open Access (NOA). Read more about Neurology® Open Access in this editorial, and visit the Neurology® Open Access website.   Disclosures can be found at Neurology.org.

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Mehari Gebreyohanns discuss the essence of humanistic care.   

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Mehari Gebreyohanns discuss the Bahir Dar Outreach for Neurology Education (BORNE) initiative. 

Dr. Jeff Ratliff talks with Dr. Mehari Gebreyohanns, the recipient of the 2025 Ted Burns Humanism in Neurology Award, about his journey into stroke care, the BORNE initiative, and the challenges faced in global neurology. Disclosures can be found at Neurology.org.

Dr. Jeff Ratliff delves into the common causes of acquired dystonia and highlights evidence-based treatment strategies for effective management.    

Dr. Jeff Ratliff provides an in-depth look at orthostatic tremor, a rare and often overlooked movement disorder, highlighting its symptoms, challenges, and the importance of early detection. Show references: https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.13454 

In part two of this series, Dr. Jeff Ratliff and Dr. John W. Winkelman highlight the key insights on medication management for patients dealing with troublesome restless leg symptoms. Show references: https://jcsm.aasm.org/doi/10.5664/jcsm.11390

In part one of this series, Dr. Jeff Ratliff and Dr. John W. Winkelman discuss clinical lessons from the guidelines with regards to monitoring iron levels and prescribing supplemental iron for patients with restless leg syndrome. Show references: https://jcsm.aasm.org/doi/10.5664/jcsm.11390

Dr. Jeff Ratliff talks with Dr. John W. Winkelman about the new clinical practice guidelines for treating restless legs syndrome and periodic limb movement disorder, covering diagnosis, treatment options, and future management insights. Read the related article in the Journal of Clinical Sleep Medicine. Disclosures can be found at Neurology.org. 

In part two of this two-part series, Dr. Jeff Ratliff and Drs. Rachel Gottlieb-Smith and Kathryn Xixis discuss the potential dangers or pitfalls of using AI to help review residency applications. Show reference: https://www.neurology.org/doi/10.1212/NE9.0000000000200150  

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Ron Postuma discuss how clinicians should approach serological antibody testing in patients with REM behavior disorder or other associated neurologic symptoms. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200311 

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Ron Postuma discuss how frequently the IGLON5 antibody is identified among patients with idiopathic REM behavior disorder. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200311 

Dr. Jeff Ratliff talks with Dr. Ron Postuma about the clinical features associated with IgLON5 positivity, emphasizing the implications for practitioners in diagnosing and treating sleep and movement disorders. Read the related article in Neurology: Neuroimmunology & Neuroinflammation.  Disclosures can be found at Neurology.org.

In part one of this two-part series, Dr. Jeff Ratliff and Drs. Rachel Gottlieb-Smith and Kathryn Xixis discuss the potential advantages that the increasing accessibility of artificial intelligence presents for the identification and recruitment of the next generation of neurologists. Show reference: https://www.neurology.org/doi/10.1212/NE9.0000000000200150 

Dr. Jeff Ratliff talks with Drs. Rachel Gottlieb-Smith and Kathryn Xixis about the impact of artificial intelligence on residency recruitment in neurology, focusing on its potential benefits and pitfalls. Read the related article in Neurology: Education. Disclosures can be found at Neurology.org.

Drs. Jeff Ratliff, Nanditha Rajamani, and Andy Horn discuss the potential for wider use of algorithmic or computational approaches to guide clinical DBS programming in the clinic and the remaining hurdles. Show reference:  https://www.nature.com/articles/s41467-024-48731-1

Drs. Jeff Ratliff, Nanditha Rajamani, and Andy Horn discuss what this study taught us about the use of deep brain stimulation when taking into account certain white matter tracts associated with key clinical Parkinson motor symptoms. Show reference: https://www.nature.com/articles/s41467-024-48731-1 

Dr. Jeff Ratliff talks with Drs. Nanditha Rajamani and Andy Horn about the challenges faced in current deep brain stimulation practices and the potential for data-driven approaches to enhance treatment outcomes. Read the related article in Nature Communication. Disclosures can be found at Neurology.org.

In part two of this two-part series, Drs. Jeff Ratliff, Michiko K. Bruno, and Lawrence Golbe discuss essential advice for general neurologists who suspect a patient might have an atypical disorder. Show reference: https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200345 

In part one of this two-part series, Drs. Jeff Ratliff, Michiko K. Bruno, and Lawrence Golbe discuss practical tips for recognizing when a patient's response to levodopa may indicate the need for an alternate diagnosis. Show reference: https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200345 

Dr. Jeff Ratliff talks with Drs. Michiko K. Bruno and Lawrence Golbe about a practical diagnostic algorithm for atypical parkinsonian disorders, emphasizing the importance of recognizing these conditions in clinical practice. Read the related article in Neurology: Clinical Practice. Disclosures can be found at Neurology.org.  

In the second part of this two-part series, Dr. Jeff Ratliff and Dr. Calum Hamilton discuss the clinical criteria that listeners should look out for, indicating a subtype of mild cognitive impairment known as DLB, which could potentially progress into a full dementia with Lewy body phenotype. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499  

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Calium discuss the risk of developing dementia among patients with MCI at three or five-year time points. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499   

Dr. Jeff Ratliff talks about the FDA approval of Crexont for the treatment of Parkinson disease.  Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2808496

Dr. Jeff Ratliff discusses an exciting study in the world of deep brain stimulation for Parkinson disease.  Show reference: https://www.nature.com/articles/s41591-024-03196-z

Dr. Jeff Ratliff talks with Dr. Calum Alexander Hamilton about the importance of tracking and managing patients with MCI, especially those with Lewy body pathology.  Read the related article in Neurology.  Disclosures can be found at Neurology.org.  

In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699 

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss why clinicians should be cautious when relying too much on dopaminergic imaging. Show reference: https://doi.org/10.1212/WNL.0000000000209453 

Dr. Jeff Ratliff talks with Dr. Daniel Weintraub about the long-term dementia risk in Parkinson disease using data from two large, ongoing, prospective, observational studies. Read the related article in Neurology.  Disclosures can be found at Neurology.org.

Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss the strengths of dopamine transporter imaging or DAT imaging in diagnosing patients with Parkinsonian disorders. Show references: https://doi.org/10.1212/WNL.0000000000209453 

Dr. Jeff Ratliff talks with Dr. Eduardo De Pablo-Fernández about the strengths of DAT imaging in diagnosing patients with Parkinsonian disorders. Read the related article in Neurology.  Disclosures can be found at Neurology.org.

In the last episode of this three-part series, Dr. Jeff Ratliff discusses how to approach patients presenting with emergent rigidity and difficulty moving.

In the second episode of this three-part series, Dr. Jeff Ratliff provides a rapid overview of hyperkinetic disorders that require urgent attention.

In the first episode of this three-part series, Dr. Jeff Ratliff discusses a few key points to help recognize and initiate treatment for patients with movement disorder emergencies, focusing on the initial approach to these disorders. It is important to consider medications, labs, and imaging as part of the evaluation process.

In part two of this two-part series, Dr. Jeff Ratliff talks with Dr. Avindra Nath about new research related to post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr. Jeff Ratliff and Dr. Avindra Nath discuss clinical pearls and advice to better recognize and diagnose patients with post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. 

Dr. Jeff Ratliff talks with Dr. Avindra Nath about new research related to post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. Disclosures can be found at Neurology.org.

In part 2 of this series, Dr. Jeff Ratliff and Dr. Maureen Leehey discuss non-motor symptoms such as sleep and cognition in patients with Parkinson disease taking a cannabis extract versus placebo.  Show reference: https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29768 

Dr. Jeff Ratliff and Dr. Maureen Leehey discuss the short-term efficacy and tolerability of high-CBD/low-THC cannabis extract on the motor symptoms in patients with Parkinson disease. Show reference: https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29768   

Dr. Jeff Ratliff talks with Dr. Maureen Leehey about the short-term efficacy and tolerability of high-CBD/low-THC cannabis extract on the motor symptoms in patients with Parkinson disease.  Read the related article in the International Parkinson and Movement Disorder Society.  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. Disclosures can be found at Neurology.org.

Dr. Jeff Ratliff talks with Dr. Chris Gibbons about the use of skin biopsies to detect phosphorylated α-synuclein in individuals with synucleinopathies such as Parkinson disease, multiple system atrophy, dementia with Lewy bodies, and pure autonomic failure. Read the related article in JAMA.  Disclosures can be found at Neurology.org.

Dr. Jeff Ratliff talks with Drs. Dara V. F. Albert and Afsaneh Talai about understanding the gaps in resident education on psychogenic nonepileptic seizures. Read the related article in Neurology: Education.  Disclosures can be found at Neurology.org.